Inhaled nitric oxide (iNO) is used in the treatment and diagnosis of a variety of cardiorespiratory disorders in children. It is licensed for use in term and near-term neonates (> 34 weeks gestation) with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygentation (ECMO). It is being used increasingly in older children and those with cardiac disorders.

The European Inhaled Nitric Oxide Registry is an European Collaboration which was established originally by a group of interested clinicians in 2006. It has been running in its current format since September 2009. Clinical and demographic information about children treated with iNO in Europe is collected in order to enhance clinical care and inform future research projects.

If you are interested in contributing to the Registry, or would like any more information, please contact one of the following Steering Committee members:
Dr. Nim Subhedar nim.subhedar@lwh.nhs.uk
Dr. Baldvin Jonsson baldvin.Jonsson@ki.se
Dr. Ola Ingemansson ola.ingemansson@vgregion.se
Dr. Paula Rautainen paula.rautiainen@hus.fi